Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: Are there molecular markers in the primary tumour that predict for 5-year clinical outcome?

Annals of Oncology

Volumn 14, Issue 3, 2003, Pages 406-413

  Bonnefoi, Herve ^a   Diebold Berger, S ^a   Therasse, P ^b   Hamilton, A ^c   van de Vijver, M ^d   MacGrogan, G ^e   Shepherd, L ^f   Amaral, N ^g   Duval, C ^h   Drijkoningen, R ⁱ   Larsimont, D ^c   Piccart, M ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b EORTC DATA CENTER   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e INSTITUT BERGONIÉ   (France)

^f Queen's Cancer Research Institute   (Canada)

^g CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^h CENTRE HENRI BECQUEREL   (France)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breast cancer; Locally advanced inflammatory breast cancer; Neoadjuvant chemotherapy; p53

Indexed keywords

CYCLIN D1; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TUMOR BIOPSY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLIN D1; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 12244311223     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg108     Document Type: Article

References (37)

1. Pegram MD, Finn RS, Arzoo K et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15: 537-547.
2. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334-2356.
3. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
4. Lowe SW, Bodis S, McClatchey A et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810.
5. Aas T, Borresen AL, Geisler S et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 2: 811-814.
6. Geisler S, Lonning PE, Aas T et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61: 2505-2512.
7. Therasse P, Mauriac L, Jassem J et al. Final results of a randomised phase III trial comparing CEF (cyclophosphamide, epirubicin, 5FU) with a dose intensified EC + G-CSF (epirubicin, cyclophosphamide + filgrastim) in locally advanced breast cancer. An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003; In press.
8. Hayes DF, Trock BJ, Harris AL. Assessing the clinical impact of prognostic factors: when is 'statistically significant' clinically useful? Breast Cancer Res Treat 1998; 52: 305-319.
9. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
10. Clahsen PC, van de Velde CJ, Duval C et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998; 16: 470-479.
11. Allred DC, Swanson PE. Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol 2000; 113: 171-175.
12. Wintzer HO, Zipfel I, Schulte-Mönting J et al. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991; 67: 421-428.
13. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-3827.
14. McIntosh GG, Anderson JJ, Milton I et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 1995; 11: 885-891.
15. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
16. Mantel N. Evaluation of survival data and the two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
17. Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34: 187-202.
18. Breslow N. Comparison of survival curves. In Buyse ME, Staquet MJ, Sylvester RJ (eds): Cancer clinical trials methods and practice. Oxford, UK: Oxford Medical Publications 1988; 382-406.
19. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994; 69: 979-985.
20. Faille A, Cremoux P, Extra JM et al. p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer 1994; 69: 1145-1150.
21. Honkoop AH, van Diest PJ, de Jong JS et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998; 77: 621-626.
22. Allred DC. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.
23. Early Breast Cancer Trialist' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
24. Rubens RD, Armitage P, Winter PJ et al. Prognosis in inoperable stage III carcinoma of the breast. Eur J Cancer 1977; 13: 805-811.
25. Trock BJ, Yamauchi H, Brotzman M et al. C-erbB2 as a prognostic factor in breast cancer: a meta-analysis. Proc Am Soc Clin Oncol 2000; 19: 97a (Abstr).
26. Sjögren S, Inganäs S, Norberg T et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 173-182.
27. Berns EM, Foekens JA, Vossen R et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000; 60: 2155-2162.
28. Chappuis PO, Estreicher A, Dieterich B et al. Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay. Int J Cancer 1999; 84: 587-593.
29. MacGrogan G, Mauriac L, Durand M et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GSTπ. Br J Cancer 1996; 74: 1120-1125.
30. Makris A, Powles TJ, Dowsett M et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast cancer. Clin Cancer Res 1997; 3: 593-600.
31. Linn SC, Pinedo HM, van Ark-Otte J et al. Expression of drug resistance proteins in breast cancer in relation to chemotherapy. Int J Cancer 1997; 71: 787-795.
32. Rozan S, Vincent-Salomon A, Zafrani B et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998; 79: 27-33.
33. Fan S, Cherney B, Reinhold W et al. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res 1998; 4: 1047-1054.
34. Lanni JS, Lowe SW, Licitra EJ et al. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci USA 1997; 94: 9679-9683.
35. 2/M arrest and apoptosis. Nature Med 1996; 2: 72-79.
36. Flaman JM, Frebourg T, Moreau V et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995; 92: 3963-3967.
37. Bonnefoi H, Ducraux A, Movarekhi S et al. p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients. Br J Cancer 2002; 86: 750-755.